Safety and Effectiveness of a Biosimilar Recombinant Growth Hormone in Adults with Growth Hormone Deficiency: Analysis of Final Data from PATRO Adults, an International Post-Marketing Surveillance Study
Final data from PATRO Adults confirm that biosimilar rhGH (Omnitrope) is not associated with any unexpected safety signals, with no evidence of increased diabetogenic or carcinogenic risk, and is effective in real-world clinical practice.
Authors
- Charlotte Höybye (ORCID: https://orcid.org/0000-0002-3980-1927)
- Anca Boldea
- Altaher Esmael
- Markus Zabransky
- Robert Douglas Murray (ORCID: https://orcid.org/0000-0001-6730-6109)
- Günter K. Stalla
- Dragan Urosevic
- Suat Şimşek (ORCID: https://orcid.org/0000-0002-0725-2468)
- Paolo Beck‐Peccoz
Institutions
- Novartis (Switzerland) (CH)
- Karolinska University Hospital (SE)
- Leeds Teaching Hospitals NHS Trust (GB)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Karolinska Institutet (SE)
- LMU Klinikum (DE)
- Ospedale Maggiore (IT)
- Hexal (Germany) (DE)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/dddt.s471967
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hexal AG